AUM LifeTech and AUM BioTech Teams Up To Develop Covid-19 Pandemic Treatment

AUM LifeTech, a US-based leading biotechnology focus on delivering RNA silencing therapeutics, has announced on Tuesday May 5, 2020 that the company is collaborating with the AUM BioTech, a generic biotechnology company, to launch a new initiative called the ‘Knockdown Coronavirus’ with the aim of developing the treatment for Covid-19 Pandemic.

According to the details released by the PR Newswire News Agency, both the companies are offering self-delivering RNA silencing research products to its customers across the United States. The targeting biotechnology of AUM BioTech can be used to conduct genetic screening that would help identify new potential targets for the development of Covid-19 treatment.

Chief Executive Officer and Founder of AUM LifeTech and AUM BioTech said, “We are very excited to launch this program and serve the global scientific community, which is working tirelessly to find a cure for COVID-19 in these unique and challenging times. RNA targeting technology works by silencing (knocking down) the RNA that plays a crucial role, causing a loss of function, thus inhibiting viral replication and transmission. We are very proud to offer our RNA silencing platform, to better understand the biology of SARS-CoV-2 and its interaction with the host.”

Our goal is to provide our expertise and resources to facilitate COVID-19 research with a hope to develop a potential antiviral therapy for COVID-19 using our self-delivering FANA ASO technology. Additionally, we are actively seeking new alliances and invite the scientific community to partner with us to knockdown coronavirus and defeat COVID-19,” CEO further added.

Member of AUM LifeTech Scientific Advisory Board, Dr. John Rossi said, Coronavirus is an RNA virus. We have in the past shown and published that AUM’s self-delivering FANA ASO technology can inhibit replication of HIV (which is also an RNA virus) by selectively targeting the RNA of HIV without showing any apparent immune response.”

We are confident that AUM’s RNA silencing platform powered by FANA ASO technology can be effectively used to understand the biology of SARS-CoV-2, identify critical targets, and facilitate therapy development for COVID-19. We are excited about the prospect of seeing self-delivering FANAs ASOs as anti-coronavirus agents,” Dr. John Rossi further added.

Leave a Reply

Your email address will not be published. Required fields are marked *